Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

A merg­er be­tween Ox­i­tope Phar­ma and Arxx Ther­a­peu­tics sees the birth of clin­i­cal-stage im­munother­a­py com­pa­ny Cal­lu­na, with €75 mil­lion ($81.6 mil­lion) in its pock­ets from a Se­ries A raise.

“Things look very ex­cit­ing for the new com­pa­ny go­ing for­ward. That’s why the cur­rent in­vestors have de­cid­ed to not on­ly merge the com­pa­nies but pro­vide it with a sig­nif­i­cant run­way,” Cal­lu­na CEO John Mon­tana, the pre­vi­ous CEO of Ox­i­tope, said in an in­ter­view with End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER